GRFS · Grifols SA ADR
United States · RS rating 73 · As of 2026-11-03
| Price | 8.56 USD |
|---|---|
| 1-day change | +0.6% |
| RS rating (overall / 1M / 3M / 12M) | 73 / 90 / 80 / 44 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 30 / 29 / 50 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | +67.7% |
| Sales growth Q/Q | -4.3% |
| Distance from 52-week high | +11.9% |
| Market cap (USD) | $5.4B |